['colorectal cancer']
['capecitabine plus oxaliplatin']

        Inclusion Criteria:

          1. Performance status (ECOG) 0~2

          2. Histologically confirmed colon cancer.

          3. No prior treatment

          4. CT-defined T4 or lymph node-positive colon cancer

          5. Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 8 g/dL Bilirubin
             level ≤ 1.0 x ULN

          6. AST and ALT < 1.5 x ULN

          7. Serum creatinine ≤ 1.0 x ULN

          8. Life expectancy of ≥ 3 months

          9. Signed written informed consent

        Exclusion Criteria:

          1. Final stage with cancer cachexia

          2. Allergy for capecitabine or oxaliplatin

          3. Any evidence of extrahepatic metastases and/or primary tumor recurrence

          4. Severe organ failures or diseases, including: clinically relevant coronary disease,
             cardiovascular disorder or myocardial infarction within 12 months before study entry,
             severe psychiatric illness, severe infection and DIC
      